摘要
目的:对比康柏西普和阿柏西普对新生血管性老年性黄斑变性(nAMD)患者的视力及不良反应的影响。方法:选取2020年6月至2023年2月江阴市中医院行玻璃体腔内药物注射治疗的nAMD患者109例(109眼),根据玻璃体腔注射药物的不同将患者分为康柏西普组(57眼)与阿柏西普组(52眼),随访3个月以上,对比分析两组治疗前后的最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)、脉络膜新生血管(CNV)渗漏情况以及不良反应等指标。结果:治疗后1个月、3个月的BCVA、CMT的数值均降低[康柏西普组:(0.57±0.15)、(0.46±0.12)LogMAR,(256.27±24.58)、(237.58±25.67)μm;阿柏西普组:(0.55±0.13)、(0.44±0.13)LogMAR,(247.94±26.27)、(232.49±27.29)μm],差异具有统计学意义(均P<0.05)。两组各时间点BCVA、CMT比较,差异均无统计学意义(均P>0.05),康柏西普组与阿柏西普组CNV渗漏治疗总有效率(85.96%vs 88.46%)及不良反应发生率(19.29%vs 17.30%)比较,差异无统计学意义(P>0.05)。结论:玻璃体腔内注射康柏西普与阿柏西普均能有效恢复nAMD患者的视网膜结构、减轻黄斑水肿、减少CNV渗漏、提高患者的BCVA,且不良反应发生率低,具有良好的安全性。
Objective:To compare the effect of aflibercept with conbercept on visual acuity and adverse effects in patients with neovascular age-related macular degeneration(nAMD).Methods:One hundred and nine invalids(109 eyes)receiving intravitreal injection for nAMD in our hospital from June 2020 to February 2023 were enrolled,and divided into conbercept group(57 eyes)and aflibercept group(52 eyes)according to the drugs.Invalids were followed up for more than 3 months.Central macular thickness(CMT),best-corrected visual acuity(BCVA),vascular leakage of choroidal neovascularisation(CNV)lesions,and adverse reactions were compared between the 2 groups.Results:A reduction in BCVA((0.57±0.15),(0.46±0.12)LogMAR,(0.55±0.13),(0.44±0.13)LogMAR)and CMT((256.27±24.58),(237.58±25.67)μm,(247.94±26.27),(232.49±27.29)μm)after 1 month and 3 month mon after treatment was detected in both groups(P<0.05).The BCVA and CMT at different time points yielded no statistical difference between the 2 groups(P>0.05).The total effective rate of CNV leakage treatment(85.96%vs 88.46%)and overall adverse reaction rate(19.29%vs 17.30%)demonstrated no statistical difference between the 2 groups(P>0.05).Conclusion:Both intravitreal injections of conbercept and that of aflibercept are effective in restoring retinal structure,reducing macular oedema,decreasing CNV leakage,and improving BCVA in patients with nAMD,with a low incidence of adverse effects and a good safety profile.
作者
田弘亚
钱维燕
缪亚香
周云佳
肖爱萍
TIAN Hong-ya;QIAN Wei-yan;MIAO Ya-xiang;ZHOU Yun-jia;XIAO Ai-ping(Department of Ophthalmology,Jiangyin Hospital of TCM,Jiangyin 214400,China)
出处
《中国药物应用与监测》
CAS
2023年第5期304-307,共4页
Chinese Journal of Drug Application and Monitoring
关键词
新生血管性老年性黄斑变性
康柏西普
阿柏西普
最佳矫正视力
不良反应
Neovascular age-related macular degeneration
Conbercept
Aflibercept
Best corrected visual acuity
Adverse reaction
